Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Polydex Pharmaceuticals Ltd. (POLXF : OTC)

• Company Description    Polydex Pharmaceuticals Limited develops and manufactures biotechnology-based products serving markets primarily across North America and globally. The Company primarily focuses on the manufacture and development of Dextran and derivative products. Its product is marketed in human pharmaceutical market and bulk pharmaceutical intermediates for the worldwide pharmaceutical industry. The company was formerly known as Polydex Chemicals Limited and changed its name to Polydex Pharmaceuticals Limited. Polydex Pharmaceuticals Limited is based in Toronto, Canada. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $ Daily Weekly Monthly 20 Day Moving Average: shares Shares Outstanding: (millions) Market Capitalization: $ (millions) Beta: 52 Week High: $2.01 52 Week Low: $0.55 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week % % 12 Week % % Year To Date % %

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 421 COMSTOCK ROAD - TORONTO,A6 M1L 2H5 CAN ph: 416-755-2231 fax: - polydexir@gmail.com http://www.polydex.com

• General Corporate Information    Officers George G. Usher - Chief Executive Officer; Chairman of the Board and Sharon L. Wardlaw - Chief Operating Officer; Secretary and Treasurer David P. Jamestee - Chief Financial Officer Derek Lederer - Director Joseph Buchman - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 731728200 SIC: 2810 Fiscal Year Fiscal Year End: January Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: Most Recent Split Date: 6.00 (0.10:1) Beta: Market Capitalization: $ (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: % Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 07/31/25 - - 04/30/25 - - 01/31/25 - - ROA 07/31/25 - - 04/30/25 - - 01/31/25 - - Current Ratio 07/31/25 - - 04/30/25 - - 01/31/25 - - Quick Ratio 07/31/25 - - 04/30/25 - - 01/31/25 - - Operating Margin 07/31/25 - - 04/30/25 - - 01/31/25 - - Net Margin 07/31/25 - - 04/30/25 - - 01/31/25 - - Pre-Tax Margin 07/31/25 - - 04/30/25 - - 01/31/25 - - Book Value 07/31/25 - - 04/30/25 - - 01/31/25 - - Inventory Turnover 07/31/25 - - 04/30/25 - - 01/31/25 - - Debt-to-Equity 07/31/25 - - 04/30/25 - - 01/31/25 - - Debt-to-Capital 07/31/25 - - 04/30/25 - - 01/31/25 - -

Powered by Zacks Investment Research ©